Please assess the completion status of the following clinical trial:

Trial Title: Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Be age ≥ 18 years old.~* Have Karnofsky performance status score ≥ 70.~* Be scheduled to receive one of 3 myeloablative conditioning regimens (defined in population) followed by allogeneic SCT for hematological malignancy.~* Have anticipated in-patient status for 14 to 20 days from the time of transplant.~* Be willing and capable of swishing/gargling oral gel/solution as required per protocol.~* Be willing and capable of completing the assessments and adhering to protocol requirements.~* Be willing and able to provide written informed consent.~To be randomized to begin treatment, subjects randomized to Arms 2 or 3 must also meet the following criterion:~-Be diagnosed with G1 or G2 OM via WHO OM scale during observation period from conditioning to Day +14.~Exclusion Criteria:~* Subjects receiving pre-transplant conditioning/GVHD prophylaxis regimens other than those defined, herein.~* Use of topical or systemic agents/treatments for OM within 2 weeks of treatment day 1.~* Evidence of uncontrolled infection (oral/oropharyngeal or systemic), including oral herpes or unexplained febrile illness (≥ 99.5F /37.5C) requiring systemic anti-infectives, within 7d of treatment Day 1.~* Subjects with active oral lesions or other mouth/throat soreness within 7d of study randomization.~* Any other criteria, in the opinion of the investigator that would make the subject unsuitable for study participation.~For subjects randomized to Treatment Arms 2 or 3 during observation period:~-OM ≥ G3 diagnosed prior to initiating randomized treatment during observation period (conditioning through Day +14; i.e., missed treatment window).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Gelclair at time of conditioning) (Type: EXPERIMENTAL): All subjects in study Arm 1 will receive GEL starting on the first day of conditioning.
- Arm 2 (Gelclair when OM diagnosed) (Type: ACTIVE_COMPARATOR): Subjects in Arm 2 will be observed from initiation of conditioning to Day +14. If subjects develop G1 or G2 OM via WHO OM scale during this period, they will at that time be randomized to immediately receive GEL.
- Arm 3 (MMW when OM diagnosed) (Type: ACTIVE_COMPARATOR): Subjects in Arm 2 will be observed from initiation of conditioning to Day +14. If subjects develop G1 or G2 OM via WHO OM scale during this period, they will at that time be randomized to immediately receive MMW.

Based on this trial design, predict the completion outcome and termination type (if applicable).